Islets for US
Collaborative
Conferences with our Presentations and Abstracts
American Society of Transplant Surgeons
ASTS Winter Symposium, Miami, FL
Fillman N. Does CXCL8 inhibitor (Reparixin) improve islet engraftment and clinical outcomes after islet allotransplantation? University of Chicago preliminary results from a phase 3 multicenter randomized, double-blinded, prospective study.
selected for oral presentation
8th EPITA Symposium
Innsbruck, Austria
Golebiewska J. Does CXCL8 inhibitor (Reparixin) improve islet engraftment and clinical outcomes after islet allotransplantation? University of Chicago preliminary results from a phase 3 multicenter randomized, double-blinded, prospective study.
selected for oral presentation
26th Annual Charles B. Huggins Symposium, Chicago, IL
1. Para M/ Damian Grybkowski. Pain resolution and glycemic control in pediatric patients after total pancreatectomy with islet cell autotransplantation for chronic pancreatitis.- selected for oral presentation.
2. Antic F. Is there any Prognostic Value of Diabetes-Associated Autoantibody Levels for Predicting Islet Graft Function in Patients with Long-Standing Type 1 Diabetes Mellitus?
3. Bachul P. Does a new CXCR8 inhibitor (Reparixin) improve islet cell engraftment and clinical outcomes after pancreatic islet allotransplantation in patients with type 1 diabetes mellitus? A randomized, double blind, prospective study.
American Transplant Congress
Boston, MA
Bachul P. Does the Reparixin (CXCR1/2 Inhibitor) Improve Islet Cell Engraftment and Clinical Outcomes after Pancreatic Islet Allotransplantation in Patients with Type 1 Diabetes Mellitus? A Randomized, Double-Blind, Prospective Study.
Perez Gutierrez A. KDPI Significantly Correlates With Reperfusion Biopsy Findings
American Diabetes Association,
79th Scientific Sessions, San Francisco, CA
Oral presentations:
1. Grybowski D. BETA-2 Calculated Based on Single Fasting Blood Sample Allows to Define and Discriminate between Optimal and Suboptimal Islet Allograft Function Prior to the Clinical Need for Insulin Support. Read Link
2. Bachul P. Does the Reparixin (CXCR1/2 Inhibitor) Improve Islet Cell Engraftment and Clinical Outcomes after Pancreatic Islet Allotransplantation in Patients with Type 1 Diabetes Mellitus? A Randomized, Double-Blind, Prospective Study. Read Link
3. Anteby R/Luncander A. Is There Any Prognostic Value of Diabetes-Associated Autoantibody Levels for Predicting Islet Graft Function in Patients with Long-Standing Type 1 Diabetes Mellitus? Read Link
International Pancreas and Islet Transplantation Association
17th World Congress, Lyon, France
Oral presentations:
1. P Bachul. Is there any Prognostic Value of Diabetes-Associated Autoantibody Levels for Predicting Islet Graft Function in Patients with Long-Standing Type 1 Diabetes Mellitus?
2. Golebiewska. BETA-2 Based On Single Fasting Blood Sample Allows To Define and Discriminate Optimal And Suboptimal Islet Allograft Function Prior to The Need For Reintroduction of Insulin Support.
3. Bachul P. Does A CXCR1/2 Inhibitor (Reparixin) Improve Islet Cell Engraftment And Clinical Outcomes After Pancreatic Islet Allotransplantation In Patients With Type 1 Diabetes Mellitus? Results of A Randomized, Double Blind, Prospective Study from the University of Chicago.
4. Golebiewska J. Utilization of an "old school" supplemental purification technique allowed safe intraportal pancreatic islet transplantation. The first case ofislet allotransplantation in Medical University of Gdańsk, Poland.
5. Bellin M. A Randomized and Blinded Trial of Infusion of the CXCL8-inhibitor Reparixin in Autologous Islet Transplant Recipients.
8th EPITA Symposium
Innsbruck, Austria
1. Golebiewska J. Assessment of simple indices based on a single fasting blood sample in search for an optimal tool to estimate beta cell function after total pancreatectomy with islet autotransplantation.
2. Bachul P. BETA-2 score for early detection of islet allograft decline and monitoring of islet function
The 25th Annual Charles Huggins Research Symposium
UCMC, Chicago, IL
1. Bachul P. Estimation of beta cell function after total pancreatectomy with islet autotransplantation using single fasting blood sample based indices and modified Igls score
2. Fillman N. External validation of the newly developed BETA-2 scoring system for pancreatic islet graft function assessment
3. Fillman N. BETA-2 score is an excellent tool for monitoring of islet allograft function and early detection of transplant dysfunction
4. Kijek M. Pain resolution with good glucose control in pediatric patients with chronic pancreatitis after total pancreatectomy with islet cell autotransplantation
5. Kijek M. Broad Non-Neuraxial Analgesia Reduces Risk of Portal Vein Thrombosis After Total Pancreatectomy and Autologous Islet Transplantation Comparing to the Neuraxial Analgesia with the adequate postoperative pain control
6. Pavelko Y. Early infectious complications post total pancreatectomy with islet autotransplantation
American Transplant Congress (ATC)
Seattle, WA
1. Golebiewska J. Early infectious complications post total pancreatectomy with islet autotransplantation. READ
2. Golebiewska J. Estimation of beta cell function after total pancreatectomy with islet autotransplantation using single fasting blood sample based indices and modified Igls score
3. Bachul P. BETA-2 score is an excellent tool for monitoring of islet allograft function and early detection of transplant dysfunction
27th International Congress of The Transplantation Society (TTS) Madrid, Spain
1. Golebiewska J. Comparative evaluation of simple indices using a single fasting blood sample to estimate beta cell function after total pancreatectomy with islet autotransplantation
2. Golebiewska J. Early infectious complications post total pancreatectomy with islet autotransplantation. READ
3. Bachul P. BETA-2 score allows for convenient and precise monitoring of islet function and early detection of islet dysfunction